Families prescribed Monarch can now pay with digital wallets or third-party installment plans at checkout LOS ANGELES, Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. today announced expanded payment options for patients prescribed the Monarch eTNS® System, the first non-drug treatment for pediatric ADHD cleared by the U.S. Food and Drug Administration. Patients receiving a Monarch eTNS prescription can now choose from a wider range of payment methods at checkout, incl

U.S. Commercial launch of Gen 2 Monarch System commencing today, July 21, 2026 Gen 2 Monarch device provides an enhanced patient experience while delivering clinically proven therapeutic stimulation of the trigeminal nerve U.S. launch supported by a waitlist of more than 1,500 patients, caregivers, and providers Visit www.monarch-etns.com for additional information on how to obtain the Gen 2 Monarch® device LOS ANGELES, July 21, 2026 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Lo

Transaction is Hopewell’s first commercial license of proprietary lipid nanoparticles (LNPs) Hopewell’s LNPs are the preferred delivery solution for the cancer vaccine technology that Foxcroft licensed from Tufts University in 2025 Foxcroft will conduct its first large mammal (canine) trial in mid-2026, using Hopewell’s LNPs WOBURN, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Hopewell Therapeutics, Inc. , a Boston-based next-generation lipid nanoparticle (LNP) company (“ Hope

Armstrong Asia of Singapore selected as NeuroSigma’s manufacturing partner Investment led by Checkmate Capital as part of strategic partnership with Armstrong Asia First commercial units to be delivered in March 2026 LOS ANGELES, Dec. 15, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. , a Los Angeles-based bioelectronics company, today announced completion of an approximately $1 million investment into a high-volume manufacturing line for the second-generation Monarch exte

Company dispensed over 1,000 FDA-cleared systems in pilot phase; unveils new website and second-generation device for early 2026 launch LOS ANGELES, Nov. 18, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. , a Los Angeles-based bioelectronics company, today announced the successful completion of its pilot commercialization program for the first-generation Monarch eTNS ® System and the launch of a new website in preparation for release of its second-generation Monarch device. The

Peer-reviewed results of PET neuroimaging demonstrate rapid and profound changes to humans receiving eTNS LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. , a Los Angeles-based bioelectronics company, today announced a new publication in the journal Neuromodulation: Technology at the Neural Interface. The publication, titled "Oxygen-15 Labeled Positron Emission Tomography During External Trigeminal Nerve Stimulation ," is the first-ever to report the real-tim

THIO-101 Phase 2 trial to enroll patients in the U.S. as part of the expansion of the study in third-line treatment for advanced...

SINGAPORE, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Armstrong Asia, a leading Singapore-based manufacturer of flexible material solutions with...